All study participants | |
Demographic factors | |
Subjects | 96 |
Age years | 34.5 (28.9–39.2) |
Male sex | 67 (70) |
Race | |
Black | 83 (86) |
Mixed | 13 (14) |
Intensive phase treatment | |
HRZE | 19 |
HR35ZE | 20 |
HRZQ | 19 |
HR20ZQ | 19 |
HR20ZM | 19 |
Pyrazinamide dose mg | 1200 (1200–1600) |
Pyrazinamide dose mg·kg−1 | 25.7 (24.0–28.3) |
Clinical factors | |
Weight kg | 54.0 (48.9–56.5) |
Body mass index kg·m−2 | 19.2 (17.6–20.5)# |
Body mass index <18.0 kg·m−2 | 25 (26)# |
HIV positive | 2 (2) |
Cavity on baseline chest radiography | 66 (68.8) |
Data are presented as n, median (interquartile range) or n (%). HRZE: isoniazid-rifampicin-pyrazinamide-ethambutol intensive phase regimen (subscript indicates mg·kg−1 dose); HRZQ: isoniazid-rifampicin-pyrazinamide-SQ109 (subscript indicates mg·kg−1 dose); HRZM: isoniazid-rifampicin-pyrazinamide-moxifloxacin (subscript indicates mg·kg−1 dose). #: one patient had height missing.